August 27, 2007
PISCATAWAY, N.J.—Sabinsa Corp. announced a final judgment was entered in late June in U.S. District Court in New Jersey in a patent infringement lawsuit against DNP International Inc. The final consent judgment stipulated Sabina’s U.S. trademarks (No. 5,972,382, No. 5,804,596) covering the use of piperine black pepper extract (Bioperine®) and Coleus forskohlii (ForsLean®), respectively, were valid and properly issued by the U.S. Patent and Trademark Office. DNP agreed in the final consent judgment to “cease, directly and indirectly, from importing, ... making, using, marketing, advertising for sale, or selling” piperine or coleus in the United States.
The same patents are at issue in a new lawsuit filed by Sabinsa in U.S. District Court in the Eastern District of New York against BioGreen NutraChem Inc. Sabinsa alleged in its complaint that BioGreen has been unlawfully marketing and distributing piperine and Coleus forskohlii for uses that Sabinsa researched and patented in the late 1990s.
You May Also Like
CRN petition to FTC: RCTs aren’t required to substantiate ‘health-benefit’ claimsSep 22, 2023
Collagen peptide ingredient solutions for seniors’ changing needs – infographicSep 19, 2023
Radicle Insights—Covid Eris and dietary supplements: separating fact from fictionSep 21, 2023
More bioavailable hyaluronic acid complex for today’s beauty-from-within consumer – snapshotSep 18, 2023